Pharma's Almanac | Roundtable

59 Articles Available

1 3

International Markets

In what international markets do you anticipate significant developments in the near future?

PAO-01-23-RT-02

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

PAO-01-23-RT-01

Future of the Industry

What key indicators do you look at to predict the future of this industry?

PAO-10-022--RT-02

Sustainability

What is your plan to build a more sustainable business practice in the coming years?

PAO-10-022--RT-01

Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

PAO-06-022--RT-01

Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

O-06-022--RT-01

Leadership

Q: What’s the key to being a leader in the industry?

PAO-03-022-RT-02

Milestones

Q: What important company milestone do you anticipate reaching in 2022?

PAO-03-022-RT-01

Personalized and Precision Medicine

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

PAO-12-21-RT-01

Therapeutic Progress

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

PAO-12-21-RT-02

Social Media Marketing

Q: What’s the next “big thing” on the horizon that will significantly alter the pharma/biopharma market, your operations, or the way you do business?

Evolving Technologies

Q: What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Evolving Technologies

Q: How have evolving technologies like artificial intelligence (AI) and machine learning (ML) changed how you conduct research, manufacturing, or business?

PAO-06-21-RT-1

Social Media Marketing

Q: How is your organization using social media to extend your marketing efforts?

PAO-06-21-RT-2

Business Development

Q: How are you growing your business development activities in the absence of conventional trade shows and other traditional business development/marketing activities?

PAO-03-21-NI-02

COVID-19 Impacts

Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?

PAO-03-21-NI-01

COVID-19 Impacts

Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?

PAP-Q4-20-NI-006

Roundtable

Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?

PAP-Q4-20-NI-007

Post COVID-19 Supply Chain

Q: How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?

PAP-Q3-20-NI-007

Roundtable

Q: What steps is your company taking to address drug pricing issues?

PAP-Q3-20-NI-008

COVID-19

Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

PAP-Q2-20-RT-001

Roundtable

Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

PAP-Q2-20-RT-002

M&A

Q: How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?

PAP-Q1-20-NI-008

Technology

Q: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?

PAP-Q1-20-NI-009

1 3

Roundtable

59 Articles Available

Can't find what you're looking for? Try our advanced search.

International Markets

In what international markets do you anticipate significant developments in the near future?

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

Future of the Industry

What key indicators do you look at to predict the future of this industry?

Sustainability

What is your plan to build a more sustainable business practice in the coming years?

Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Leadership

Q: What’s the key to being a leader in the industry?

Milestones

Q: What important company milestone do you anticipate reaching in 2022?

Personalized and Precision Medicine

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

Therapeutic Progress

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

Social Media Marketing

Q: What’s the next “big thing” on the horizon that will significantly alter the pharma/biopharma market, your operations, or the way you do business?

Evolving Technologies

Q: What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Evolving Technologies

Q: How have evolving technologies like artificial intelligence (AI) and machine learning (ML) changed how you conduct research, manufacturing, or business?

Social Media Marketing

Q: How is your organization using social media to extend your marketing efforts?

Business Development

Q: How are you growing your business development activities in the absence of conventional trade shows and other traditional business development/marketing activities?

COVID-19 Impacts

Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?

COVID-19 Impacts

Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?

Roundtable

Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?

Post COVID-19 Supply Chain

Q: How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?

Roundtable

Q: What steps is your company taking to address drug pricing issues?

COVID-19

Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Roundtable

Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

M&A

Q: How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?

Technology

Q: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?